Table 1.
Radiopharmaceuticals in various clinical development phases.
| Radiopharmaceutical | Disease/disorder | Company name | Development phase/ commercial | Clinical phase identification number | References |
|---|---|---|---|---|---|
| 177Lu-labeled PSMA-617 | Metastatic Castration-Resistant Prostate Cancer | Endocyte | Phase 3 | NCT03511664 | (3) |
| 177Lu-labeled NeoBOMB1 | GRPR over expressing tumor | Novartis | Phase I/IIa | NCT03872778 | (4) |
| 166Ho microspheres | Unresectable Hepatocellular Carcinoma | Marnix Lam, UMC, Utrecht | Early Phase II Study | NCT05114148 | (5) |
| 166Ho microspheres | Neuroendocrine Tumors | Terumo | – | NCT02067988 | (6) |
| 177Lu-labeled PSMA-R2 | Metastatic castration-resistant prostate cancer (mCRPC) | Advanced Accelerator Applications | Phase 1/2 study | NCT03490838 | (7) |
| 225Ac-labeled aCD38 | Multiple myeloma | Actinium Pharmaceuticals | Open label Phase I trial | NCT02998047 | (8) |
| 177Lu-labeled CTT-1403 | Prostrate cancer | Cancer Targeted Technology | Phase 1 clinical trial | NCT03822871 | (8) |
| 227 conjugate PSMA-TTC | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Bayer | Phase 1 | NCT03724747 | (9) |
| 227Th-labeled aCD22-TTC (BAY 1862864) | Lymphoma, non-Hodgkin | Bayer | Open-label Phase I | NCT02581878 | (10) |
| 227Th-labeled MSLN-TTC | Mesothelin tumor | Bayer | Phase I/II | NCT03507452 | (11) |
| 225Ac-labeled FPX-01a | Lung cancer | J&J / Fusion Pharma | Phase I | NCT03746431 | (8, 12) |
| Radium-223 chloridea | Bone metastasis | Bayer | Commercialized | – | (13) |
a-alpha emitter based radiopharmaceutical therapy (RPT) agents.